InStride Health Secures $30M in Series B Funding to Boost Pediatric Mental Health Care

InStride Health, an innovative provider specializing in pediatric anxiety and OCD treatment, has successfully closed an oversubscribed $30M Series B funding round. This significant investment was led by General Catalyst, with continued support from .406 Ventures, Valtruis, Mass General Brigham Ventures, and Hopelab Foundation. The funding aims to enhance clinical quality and broaden market reach, facilitating better access to insurance-based mental health services.

The company's total funding now stands at $56M, fueling their mission to offer top-tier mental health care to younger populations. General Catalyst expressed strong support for InStride's mission and unique approach to delivering high-quality behavioral health care, highlighting the company's potential to address the adolescent mental health crisis.

InStride Health stands out by accepting most major insurance plans, significantly reducing wait times for treatment initiation. Their care model emphasizes Cognitive Behavioral Therapy and Acceptance and Commitment Therapy, with a focus on Exposure and Response Prevention. This approach has been developed from a decade of work by its co-founders at McLean Hospital.

The care teams at InStride Health, comprising psychiatrists, therapists, and exposure coaches, adopt an innovative method by taking treatment beyond clinic walls. This real-world approach, along with strategic partnerships with schools and referring providers, has shown excellent outcomes in patients and high satisfaction levels.

With plans to offer their services in additional states, InStride Health is dedicated to expanding its patient support ecosystem and delivering lasting results in pediatric mental health care, emphasizing the importance of accessibility and quality in treating anxiety and OCD among youth.